Boehringer Ingelheim opens Health Management Centre in China

The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools to maintain and enhance animal health.

Boehringer Ingelheim logo

Boehringer Ingelheim, world leading animal health company, announces the opening of the Boehringer Ingelheim Health Management Centre (HMC), again boosting Boehringer Ingelheim’s investment in China. The HMC records the first of its kind established by a multinational animal health company in China. Designed for world leading veterinary reference laboratories, the centre integrates animal disease and health diagnostics as well as monitoring tools to maintain and enhance animal health.

Located in Shanghai's Zhangjiang Hi-Tech Park, the HMC has an investment of nearly 3 million euros in its first phase. It is a full service reference laboratory with all diagnostic disciplines to provide comprehensive diagnosis for animal diseases, with a total projected staff of 25. The veterinary reference laboratory of the HMC, containing a serology lab, a molecular biology lab and a bacteriology lab, is currently capable of detecting more than 10 animal pathogens. It comprises state-of-the-art design, functionality, safety, and is eco-responsible. Numerous high-tech components allow for rapid detection with maximum quality control.

In addition, the centre aims to build Boehringer Ingelheim customers’ own diagnostic capabilities and capacity, functioning both as a reference laboratory and training centre which will provide comprehensive training in laboratory management, quality control, diagnostic platforms and more. The HMC is China National Accreditation Service for Conformity Assessment (CNAS) accredited.

Dr. Stephan Lange, Head of Animal Health for China's Mainland, Hong Kong and Taiwan at Boehringer Ingelheim, shared: “The opening of the HMC is another milestone for Boehringer Ingelheim in China. The HMC forms an integral part of living our ‘in China for China’ commitment. It further strengthens our ability to provide services along the full value chain for Chinese customers and highlights our commitment to continue to invest in China. We hope to best manage animal health and maximise productivity and profitability for our customers, as well as contribute to the improvement of animal and human health.”

August 12, 2019 – Boehringer Ingelheim

Article Comments

This area is not intended to be a place to consult authors about their articles, but rather a place for open discussion among pig333.com users.
Leave a new Comment

Access restricted to 333 users. In order to post a comment you must be logged in.

Not a registered user of 333?sign upand access swine prices, the search engine, ...
It is fast and free
Are you registered in 333?LOGINIf you've forgotten your password we'll send it to you here

tags